Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific ...
Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally. Massive data breach ...
Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...
Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET ...
Investing.com -- Abivax SA (EPA: ABVX) shares dipped after the company reported a wider net loss for the first nine months ...
This article first appeared on GuruFocus. Abivax SA (XPAR:ABVX) is set to release its Q3 2025 earnings on Dec 15, 2025. The ...
Abivax SA Sponsored ADR ( ($ABVX) ) has provided an announcement. On December 15, 2025, Abivax SA announced its financial results for the third ...
DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...
San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...
Quarter Results Abivax Presents Third Quarter 2025 Financial Results 15.12.2025 / 22:05 CET/CEST The issuer is solely responsible for the ...
Citizens increased the price target for Abivax SA (NASDAQ: ABVX) from $114 to $131. Citizens analyst Jason Butler maintained a Market Outperform rating. Abivax shares settled at $117.91 on Monday. See ...
As 2026 approaches, it’s prudent for investors to choose stocks that are charged up for big gains. In that context, investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results